Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 TNFSF13B [4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D03068 Belimumab [12] 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300
2 TNFSF13B [4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept [4] 13, 46, 49, 66
3 TNFSF13B [4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D10083 Tabalumab [2] 46, 49
4 TNFSF13B [4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D11127 Tibulizumab [1] 53
5 IL17F [4] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease D11550 Bimekizumab [3] 46, 97, 271
6 TNFRSF13C [5] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency D12151 Ianalumab [5] 35, 46, 49, 53, 95
7 CCR4 [4] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Kaposi sarcoma-associated herpesvirus infection, Viral carcinogenesis D09761 Mogamulizumab [1] 26
8 CCR5 [8] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis D06670 Maraviroc [2] 46, 84
9 CCR5 [8] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis D09878 Cenicriviroc [1] 94
10 IL31RA [1] Cytokine-cytokine receptor interaction D11080 Nemolizumab [1] 51
11 CSF1 [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, TNF signaling pathway, Pathways of neurodegeneration - multiple diseases, Rheumatoid arthritis D06402 Sunitinib [2] 28, 34
12 CSF1 [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, TNF signaling pathway, Pathways of neurodegeneration - multiple diseases, Rheumatoid arthritis D08552 Sunitinib [2] 28, 34
13 CSF1R [10] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer D11270 Pexidartinib [1] 34
14 CSF2 [13] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Shigellosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Rheumatoid arthritis D11343 Otilimab [2] 46, 256
15 CSF2RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D05066 Molgramostim [3] 97, 229, 299
16 CSF2RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D05712 Regramostim [1] 229
17 CSF2RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D05803 Sargramostim [7] 6, 28, 60, 62, 96, 229, 285
18 CSF2RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D09930 Mavrilimumab [2] 41, 46
19 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim [34] 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
20 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03247 Lenograstim [7] 2, 13, 16, 18, 19, 57, 65
21 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D06889 Pegfilgrastim [1] 60
22 EPOR [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin [10] 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
23 EPOR [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D09946 Peginesatide [1] 283
24 IL17RA [2] Cytokine-cytokine receptor interaction, IL-17 signaling pathway D10061 Brodalumab [2] 37, 51
25 MSTN [1] Cytokine-cytokine receptor interaction D11047 Domagrozumab [1] 113
26 MSTN [1] Cytokine-cytokine receptor interaction D11797 Apitegromab [1] 3
27 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D02691 Somatotropin [23] 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
28 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D03297 Mecasermin [6] 65, 78, 96, 168, 265, 299
29 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D04870 Mecasermin [6] 65, 78, 96, 168, 265, 299
30 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D05394 Pegvisomant [1] 78
31 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D11193 Somavaratan [1] 78
32 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D11194 Somapacitan [1] 78
33 GHR [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D11486 Lonapegsomatropin [1] 78
34 IFNA1 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
35 IFNA1 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
36 IFNA2 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
37 IFNA2 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
38 IFNA4 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
39 IFNA4 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
40 IFNA5 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
41 IFNA5 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
42 IFNA6 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
43 IFNA6 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
44 IFNA7 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
45 IFNA7 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
46 IFNA8 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
47 IFNA8 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
48 IFNA10 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
49 IFNA10 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
50 IFNA13 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
51 IFNA13 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
52 IFNA14 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
53 IFNA14 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
54 IFNA16 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
55 IFNA16 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
56 IFNA17 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
57 IFNA17 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
58 IFNA21 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
59 IFNA21 [22] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
60 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D00745 Interferon alfa-2a [1] 56
61 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D00746 Interferon beta-1b [1] 13
62 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
63 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
64 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
65 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
66 IFNAR1 [17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D11082 Anifrolumab [2] 46, 49
67 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D00745 Interferon alfa-2a [1] 56
68 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D00746 Interferon beta-1b [1] 13
69 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
70 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
71 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
72 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
73 IFNAR2 [16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer D11082 Anifrolumab [2] 46, 49
74 IFNG [27] Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D04242 Fontolizumab [1] 46
75 IFNG [27] Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D11120 Emapalumab [2] 49, 107
76 IFNGR1 [17] Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
77 IFNGR2 [16] Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
78 IL1A [18] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
79 IL1A [18] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D06635 Rilonacept [4] 51, 106, 107, 266
80 IL1A [18] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D11253 Bermekimab [1] 51
81 IL1B [35] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
82 IL1B [35] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D06635 Rilonacept [4] 51, 106, 107, 266
83 IL1B [35] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09315 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
84 IL1B [35] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09911 Gevokizumab [4] 41, 50, 56, 269
85 IL1R1 [12] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra [19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
86 IL2RA [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
87 IL2RA [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D03058 Basiliximab [6] 2, 50, 66, 97, 222, 228
88 IL2RA [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D03639 Daclizumab [8] 13, 56, 60, 65, 97, 107, 283, 284
89 IL2RB [11] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
90 IL2RG [12] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
91 IL4 [13] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Inflammatory bowel disease D03117 Binetrakin [1] 46
92 IL4R [8] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease D10354 Dupilumab [4] 51, 98, 160, 162
93 IL5 [10] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Inflammatory bowel disease D04923 Mepolizumab [4] 44, 45, 98, 162
94 IL5 [10] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Inflammatory bowel disease D08985 Reslizumab [2] 44, 98
95 IL5RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D09874 Benralizumab [5] 44, 45, 98, 162, 299
96 IL6 [41] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
97 IL6 [41] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
98 IL6 [41] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D09669 Siltuximab [2] 28, 331
99 IL6 [41] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D10080 Sirukumab [2] 41, 46
100 IL6R [11] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Pathways in cancer D02596 Tocilizumab [21] 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
101 IL6R [11] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Pathways in cancer D10161 Sarilumab [5] 41, 46, 84, 107, 271
102 IL6R [11] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Pathways in cancer D11079 Satralizumab [2] 11, 13
103 CXCR1 [5] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Phospholipase D signaling pathway, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection D08984 Reparixin [2] 298, 299
104 CXCR2 [6] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Phospholipase D signaling pathway, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, Human cytomegalovirus infection D08984 Reparixin [2] 298, 299
105 IL10 [15] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Inflammatory bowel disease, Systemic lupus erythematosus D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
106 IL11RA [3] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage D05266 Oprelvekin [2] 96, 288
107 IL12A [18] Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Lipid and atherosclerosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
108 IL12B [18] Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Lipid and atherosclerosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
109 IL13 [7] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Inflammatory bowel disease D08857 Anrukinzumab [1] 97
110 IL13 [7] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Inflammatory bowel disease D09633 Lebrikizumab [1] 85
111 IL13 [7] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Inflammatory bowel disease D09979 Tralokinumab [2] 85, 97
112 IL17A [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis D09967 Secukinumab [8] 13, 37, 41, 46, 107, 160, 269, 271
113 IL17A [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis D10071 Ixekizumab [6] 36, 37, 107, 162, 269, 271
114 IL17A [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis D11127 Tibulizumab [1] 53
115 IL17A [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis D11550 Bimekizumab [3] 46, 97, 271
116 LEPR [4] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease D05014 Metreleptin [1] 265
117 LTA [7] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection D00742 Etanercept [17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
118 LTA [7] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection D10187 Pateclizumab [1] 46
119 LTB [3] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis D08866 Baminercept [4] 13, 46, 53, 97
120 MPL [2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway D08990 Romiplostim [4] 60, 63, 64, 65
121 MPL [2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway D10306 Avatrombopag [2] 60, 63
122 NGF [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels D09387 Tanezumab [2] 226, 298
123 NGFR [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Neurotrophin signaling pathway, Transcriptional misregulation in cancer D11028 Cenegermin [2] 53, 90
124 IL20 [3] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway D11756 Fletikumab [1] 46
125 IL22 [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Inflammatory bowel disease D11953 Efmarodocokin alfa [2] 96, 97
126 IL23A [8] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
127 IL23A [8] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D10400 Tildrakizumab [2] 162, 271
128 IL23A [8] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D10438 Guselkumab [5] 37, 41, 51, 96, 97
129 IL23A [8] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D10912 Brazikumab [2] 96, 97
130 IL23A [8] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D11052 Risankizumab [4] 37, 96, 97, 271
131 IL23A [8] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D11123 Mirikizumab [3] 37, 96, 97
132 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00780 Bromocriptine [2] 6, 74
133 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00987 Cabergoline [3] 6, 74, 75
134 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D01348 Terguride [2] 51, 86
135 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D03165 Bromocriptine [2] 6, 74
136 TNFRSF17 [2] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production D11595 Belantamab mafodotin [1] 28
137 CCL2 [13] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Yersinia infection, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
138 BMPR2 [6] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Hippo signaling pathway, Signaling pathways regulating pluripotency of stem cells, MicroRNAs in cancer, Fluid shear stress and atherosclerosis D03779 Dibotermin alfa [1] 34
139 TGFB1 [27] MAPK signaling pathway, Cytokine-cytokine receptor interaction, FoxO signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Hippo signaling pathway, Th17 cell differentiation, Intestinal immune network for IgA production, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Diabetic cardiomyopathy D09620 Fresolimumab [4] 51, 85, 222, 274
140 TGFB2 [24] MAPK signaling pathway, Cytokine-cytokine receptor interaction, FoxO signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Hippo signaling pathway, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Diabetic cardiomyopathy D09620 Fresolimumab [4] 51, 85, 222, 274
141 TGFB3 [21] MAPK signaling pathway, Cytokine-cytokine receptor interaction, FoxO signaling pathway, TGF-beta signaling pathway, Hippo signaling pathway, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Renal cell carcinoma, Pancreatic cancer, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Diabetic cardiomyopathy D09620 Fresolimumab [4] 51, 85, 222, 274
142 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00742 Etanercept [17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
143 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
144 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
145 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02597 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
146 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
147 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D03441 Certolizumab pegol [8] 37, 46, 49, 96, 97, 107, 226, 271
148 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
149 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D04687 Lenalidomide [8] 16, 26, 28, 34, 49, 284, 300, 331
150 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D05393 Pegsunercept [1] 46
151 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
152 TNF [52] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09944 Ozoralizumab [1] 46
153 CCR2 [2] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor D09878 Cenicriviroc [1] 94
154 IL1R2 [6] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra [19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
155 CXCR4 [9] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer D08971 Plerixafor [6] 19, 20, 51, 65, 285, 299
156 TNFSF11 [6] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Rheumatoid arthritis D03684 Denosumab [7] 46, 50, 93, 95, 96, 274, 299
157 TNFSF13 [3] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept [4] 13, 46, 49, 66
158 IL1RL2 [1] Cytokine-cytokine receptor interaction D12066 Spesolimab [3] 37, 96, 97
159 ACVR2A [4] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D09670 Sotatercept [2] 86, 284
160 ACVR2A [4] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D10620 Bimagrumab [1] 15
161 ACVR2B [4] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D10620 Bimagrumab [1] 15
162 TNFRSF8 [1] Cytokine-cytokine receptor interaction D09587 Brentuximab vedotin [2] 49, 51
163 CD40 [13] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis D11357 Bleselumab [1] 222
164 CD40 [13] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis D11597 Ravagalimab [2] 53, 97
165 CD40 [13] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis D11610 Iscalimab [2] 49, 53
166 CD40LG [10] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis D06193 Toralizumab [1] 63